Jpmorgan Chase & CO Immucell Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ICCC
# of Institutions
26Shares Held
1.13MCall Options Held
0Put Options Held
0-
Cresset Asset Management, LLC Chicago, IL264KShares$918,7260.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA226KShares$785,0700.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny149KShares$520,2210.0% of portfolio
-
Bleichroeder LP New York, NY102KShares$353,5470.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX72.7KShares$252,9330.0% of portfolio
About IMMUCELL CORP
- Ticker ICCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 7,746,860
- Market Cap $27M
- Description
- ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive ...